A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. - Chee CE; Ooi M; Lee SC; Sundar R; Heong V; Yong WP; Ng CH; Wong A; Lim JSJ; Tan DSP; Soo R; Tan JTC; et al. (Targeted oncology, 2023)